Travere Therapeutics (TVTX) Consolidated Net Income: 2011-2024
Historic Consolidated Net Income for Travere Therapeutics (TVTX) over the last 14 years, with Dec 2024 value amounting to -$915,000.
- Travere Therapeutics' Consolidated Net Income rose 25806.00% to $25.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$28.3 million, marking a year-over-year decrease of 1014.35%. This contributed to the annual value of -$915,000 for FY2024, which is 100.35% down from last year.
- Per Travere Therapeutics' latest filing, its Consolidated Net Income stood at -$915,000 for FY2024, which was down 100.35% from $264.9 million recorded in FY2023.
- In the past 5 years, Travere Therapeutics' Consolidated Net Income ranged from a high of $264.9 million in FY2023 and a low of -$169.4 million during FY2020.
- Over the past 3 years, Travere Therapeutics' median Consolidated Net Income value was $53.0 million (recorded in 2022), while the average stood at $105.7 million.
- Per our database at Business Quant, Travere Therapeutics' Consolidated Net Income soared by 400.01% in 2023 and then tumbled by 100.35% in 2024.
- Yearly analysis of 5 years shows Travere Therapeutics' Consolidated Net Income stood at -$169.4 million in 2020, then surged by 121.96% to $37.2 million in 2021, then spiked by 42.43% to $53.0 million in 2022, then soared by 400.01% to $264.9 million in 2023, then crashed by 100.35% to -$915,000 in 2024.